Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder

Kunchok A., Malpas C., Nytrova P., Havrdova E. K., Alroughani R., TERZİ M., ...Daha Fazla

MULTIPLE SCLEROSIS AND RELATED DISORDERS, cilt.38, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.msard.2019.101868
  • Dergi Adı: MULTIPLE SCLEROSIS AND RELATED DISORDERS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Anahtar Kelimeler: Neuromyelitis optica spectrum disorder, Therapy, Predictors, Relapses, Disability, Immunosuppression, OPTICA SPECTRUM DISORDER, NEUROMYELITIS-OPTICA, MULTIPLE-SCLEROSIS, CHINESE PATIENTS, AZATHIOPRINE, RITUXIMAB, EFFICACY, REGISTRY
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Background: Aquaporin-4-IgG positive (AQP4-IgG(+)) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous system autoimmune disorder. Disease outcomes in AQP4-IgG + NMOSD are typically measured by relapse rate and disability. Using the MSBase, a multi-centre international registry, we aimed to examine the impact immunosuppressive therapies and patient characteristics as predictors of disease outcome measures in AQP4-IgG + NMOSD.